ClinicalTrials.gg
RecruitingNCT05352178SPARKLEUpdated Jul 3, 2024

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

A Phase 3 interventional study of Radiotherapy (SBRT) and/or surgery (metastasectomy) and Androgen deprivation therapy in Prostate Cancer, Prostate Cancer Recurrent and Prostate Cancer Metastatic, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
873
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven — 8 open to participants now, 11 under way, 3 of them phase 3. Prostatic Neoplasms · Universitaire Ziekenhuizen KU Leuven.

Planned enrollment
Largest of 10
873 · median 131
Started
2022
with 1 other
Phase 3
2 of 12
2 open now
Primary completion
2027-04
later than 7 of 10 live
Registered
11th of 12
by date

Among the 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven, this one has the largest planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 3, reaches primary completion later than 7 of the 10 other live ones, and was the 11th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven, or all of them as a file.
02

Study summary

The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed therapy (MDT) significantly prolongs poly-metastatic free survival (PMFS) and/or metastatic castration-refractory prostate cancer free survival (mCRPC-FS) in patients with oligorecurrent hormone sensitive prostate cancer.

Read the detailed description

Metastasis-directed therapy (MDT) has broadened the therapeutic window in patients presenting with oligorecurrent prostate cancer as it postpones the initiation of palliative androgen deprivation therapy (pADT) and its substantial side-effects for several years. Also from a biological point of view, this might be beneficial as the (early) use of ADT promotes the development of the lethal castrate-resistant state, whereby metastatic progression is driven by androgen-independent pathways. Metastasis-directed therapy with stereotactic body radiotherapy (SBRT) or surgery has shown to be able to eradicate metastases with a significant advantage concerning the pADT-free survival compared to active surveillance. And the combination of SBRT with palliative systemic treatment significantly improved overall survival (OS) when compared tot systemic treatment alone.

One of the largest retrospective analyses (191 patients) on MDT for oligorecurrent prostate cancer has been conducted previously at UZ Leuven (doi: 10.3390/cancers12082271). Estimated median pADT-free survival was 66 months and estimated median mCRPC-free survival was not reached, but 83% of patients were still free of mCRPC at 10 years.

The addition of ADT to primary radiotherapy for intermediate of high risk prostate cancer or to salvage radiotherapy has shown to improve overall survival. Within the context of SBRT for oligorecurrent disease it is not yet known whether the addition of a certain period of ADT prolongs CRPC-free survival and if so, what should be the optimal duration of this ADT administration. Moreover, the addition of an androgen receptor targeted agent (ARTA) to ADT in men with metastatic hormone sensitive prostate cancer and a treated primary tumor resulted in significantly improved clinical outcomes, also in low-volume metastatic disease.

In this clinical trial the aim is to investigate whether the addition of short-term ADT during 1 month or short-term ADT during 6 months together with an ARTA to MDT significantly prolongs poly-metastatic free survival (PMFS) and/or metastatic castration-refractory prostate cancer free survival (mCRPC-FS) in patients with oligorecurrent hormone sensitive prostate cancer.

03

Conditions studied

  • Prostate Cancer
  • Prostate Cancer Recurrent
  • Prostate Cancer Metastatic
  • Metastatic Cancer
  • Oligometastatic Disease
  • Oligometastasis
  • Hormone Sensitive Prostate Cancer

Keywords

  • Androgen deprivation therapy
  • Androgen receptor targeted agent
  • Stereotactic body radiation therapy
  • Metastasis-directed therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven initial diagnosis of prostate adenocarcinoma
  • Priory treated and controlled primary tumor
  • Biochemical recurrence defined by prostate-specific antigen (PSA) values >0,2 ng/ml (i.e., two consecutive increases) following radical prostatectomy + postoperative radiotherapy and a PSA value of 2 ng/ml above the nadir after high-dose RT.
  • Oligorecurrent disease defined as a maximum of 5 extracranial in any organ, diagnosed on PSMA PET-CT or PSMA PET-MRI reported according to the E-PSMA consensus guidelines for interpretation of PSMA-PET (26). Nodal (N1) disease can be included only when accompanied by M1a-c disease, provided that the total number of spots does not exceed 5.
  • Serum testosterone level within normal range.
  • WHO performance 0-2
  • Age >= 18 years old
  • Absence of psychological, sociological or geographical condition potentially hampering compliance with study protocol.
  • Patients must be presented at the multidisciplinary board meeting and the inclusion in the trial needs approval by this board.
  • Voluntary written of the participant or their legally authorized representative has been obtained prior to any screening procedures
    1. Use of highly effective methods of ; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.

Exclusion criteria

Exclusion Criteria:

  • Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol
  • Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial
  • Participation in an interventional Trial with an medicinal product (IMP) or device
  • Serum testosterone level at castration level.
  • PSA rise while on active treatment (LHRH-agonist, LHRH antagonist, anti-androgen, maximal androgen blockade, oestrogen)
  • Presence of poly- disease, defined as more than 5 metastatic lesions.
  • Active other than prostate cancer that could potentially interfere with the interpretation of this trial.
  • Previous treatments (RT, surgery) or comorbidities rendering new treatment with SBRT impossible.
  • Contra indications for intake of enzalutamide (seizure or any condition that may predispose to seizure; significant cardiovascular disease within the last three months including myocardial infarction, unstable angina, congestive heart failure, ongoing arrythmias of grade > 2 or a thromboembolic event).
  • Not able to understand the treatment protocol or sign .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
873 participants (estimated)

Study arms

  • Active comparator
    MDT alone

    Metastasis-directed therapy alone

    Other: Radiotherapy (SBRT) and/or surgery (metastasectomy)

  • Experimental
    MDT + 1 month of ADT

    Metastasis-directed therapy plus one month of androgen deprivation therapy (gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im)

    Other: Radiotherapy (SBRT) and/or surgery (metastasectomy) · Drug: Androgen deprivation therapy

  • Experimental
    MDT + 6 months of ADT + anzalutamide

    Metastasis-directed therapy plus 6 months of androgen deprivation therapy (gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im) and enzalutamide (4 x 40 mg each day during 6 months )

    Other: Radiotherapy (SBRT) and/or surgery (metastasectomy) · Drug: Androgen deprivation therapy · Drug: Androgen receptor targeted therapy

Interventions

  • OtherRadiotherapy (SBRT) and/or surgery (metastasectomy)

    Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions

  • DrugAndrogen deprivation therapy

    Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im

  • DrugAndrogen receptor targeted therapy

    Enzalutamide

06

What researchers measure

Primary outcomes

  1. Poly-metastatic free survival (PMFS)

    from the last day of MDT until the first day of poly-progression which is defined as the detection \> 5 new lesions at PSMA PET-CT or PSMA PET-MRI (+/- combined with MRI if needed to improve diagnostic accuracy). In case of poly-progression, pADT will be considered the standard-of-care. Other indications to start pADT are local progression of an irradiated site and/or or clinical symptoms caused by local progression. In all cases, the initiation of pADT will only be carried out after approval of the multidisciplinary tumor board. Any decision to start with pADT will be reported with date and specific reason. If recurrence occurs in 5 lesions or less a new MDT is proposed if technically feasible.

    Time frame: up to 5 years after MDT

Secondary outcomes

  1. Metastatic castration-refractory prostate cancer free survival (mCRPC-FS)

    mCRPC-FS will be calculated from the last day of MDT until the first day of diagnosis of castration-resistant prostate cancer (CRPC). CRPC is defined according to the contemporary EAU-guidelines as the time to biochemical and/or clinical progression at castrate testosterone levels (\< 50 ng/dl). Biochemical progression is defined as three consecutive PSA rises (1 week interval), of which at least 2 rises with a PSA level of \> 2 ng/ml and a rise of 50% above the nadir PSA level

    Time frame: up to 5 years after MDT

  2. Biochemical progression-free survival (bPFS)

    bPFS will be calculated from the last day of MDT until the first day of biochemical relapse (BcR). BcR is defined as three consecutive PSA rises (1 week interval), of which at least 2 rises with a PSA level of \> 2 ng/ml and a rise of 50% above the nadir PSA level.

    Time frame: up to 5 years after MDT

  3. Clinical progression free survival (cPFS)

    cPFS will be calculated from the last day of MDT until the first day of progression (local, nodal or metastatic) on PSMA PET-CT or PSMA PET-MRI. Imaging is performed in case of BcR, defined as above. Progression on PSMA PET-CT or PSMA PET-MRI will be defined as in the consensus statements on PSMA PET-CT or PSMA PET-MRI response assessment criteria in prostate cancer: * the appearance of 2 or more new PSMA PET-CT or PSMA PET-MRI lesions or increase of uptake or tumor PET volume of at least 30%. * OR the appearance of 1 new lesion with a high suspicion on PSMA PET-CT or PSMA PET-MRI

    Time frame: up to 5 years after MDT

  4. Cancer Specific Survival (CSS)

    Cancer specific survival (CSS) will be calculated from last day of treatment until PCa death.

    Time frame: up to 10 years after MDT

  5. Overall Survival (OS)

    Overall survival (OS) will be calculated from last day of treatment until death from any cause.

    Time frame: up to 10 years after MDT

  6. Acute and late toxicity scoring

    Acute and late toxicity as a result of radiotherapy will be scores using the Common Toxicity Criteria Version 5.0 (30).

    Time frame: up to 5 years after MDT

  7. Quality of life (QOL)

    Quality of life scoring using the EORTC QLQ-C30 supplement with QLQ-PR25. We will assess the quality-of-life-years with the EuroQOL classification system (EQ-5D-5L). Assessments are planned at baseline, last day of treatment, and during follow-up consultation at month M1, M3, M6, M12 and M24

    Time frame: up to 5 years after MDT

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Apr 2027, 60 months after the start.

Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's planned 60 months is below that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2022
First posted
Apr 28, 2022
StartActual
Apr 20, 2022
Primary completionEst.
Apr 25, 2027
CompletionEst.
Apr 25, 2032
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05352178
Responsible party
Sponsor
First posted
Apr 28, 2022
Start date
Apr 20, 2022
Primary completion
Apr 25, 2027 (estimated)
Completion
Apr 25, 2032 (estimated)
Last update
Jul 3, 2024

Study contacts

Kato Rans, MD
Contact
kato.rans@uzleuven.be
003216340110
Gert De Meerleer, MD, PhD
Contact
gert.demeerleer@uzleuven.be
003216347600

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion